ARK THERAPEUTICS, LTD.
12Patents
5Active
12Granted
37Portfolio score
Filing activity: Jan 26, 2000 → Jan 30, 2012 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6579855B1 | Adenovirus-mediated gene therapy | Human Necessities | 3 | Expired |
| US6982358B1 | Protective cover for injured limbs | Human Necessities | 3 | Expired |
| US7393677B2 | Avidin-pseudotyped viral vectors and their use | Chemistry; Metallurgy | 1 | Active |
| US7071183B2 | Use of inhibitors of the renin-angiotensin system | Chemistry; Metallurgy | 1 | Expired |
| US7223835B2 | VEGF peptides and their use for inhibiting angiogenesis | Human Necessities | 1 | Expired |
| US7905847B2 | Device for protecting wounds on limbs | Human Necessities | 1 | Active |
| US7208291B2 | Nucleic acids encoding biotin-binding receptors | Chemistry; Metallurgy | 0 | Expired |
| US8158789B2 | Arginine derivatives with NP-I antagonistic activity | Chemistry; Metallurgy | 0 | Active |
| US8227606B2 | Arginine derivatives with NP-1 antagonistic activity | Chemistry; Metallurgy | 0 | Active |
| US7320679B2 | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia | Human Necessities | 0 | Expired |
| US7022693B2 | Treatment of lipodystrophy | Human Necessities | 0 | Expired |
| US8334271B2 | Use of VEGF in the treatment of retarded fetal growth in pregnancy | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.